Trial Profile
A prospective, descriptive observational study of Ceftolozane/tazobactam for the treatment of multidrug resistant Pseudomonas aeruginosa
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 06 Sep 2018
Price :
$35
*
At a glance
- Drugs Cefepime/tazobactam (Primary)
- Indications Pseudomonal infections
- Focus Therapeutic Use
- 06 Sep 2018 New trial record
- 23 Aug 2018 Results published in the European Journal of Clinical Microbiology and Infectious Diseases